首页> 外文期刊>Anaesthesia and intensive care >The safety of anaesthetising biochemically hyperthyroid patients undergoing thyroidectomy-a retrospective cohort study
【24h】

The safety of anaesthetising biochemically hyperthyroid patients undergoing thyroidectomy-a retrospective cohort study

机译:甲状腺切除术治疗甲状腺切除术治疗的麻醉生物化甲亢的安全性 - 一种回顾性队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Traditionally it is recommended that hyperthyroid patients should be made euthyroid prior to thyroidectomy. However, several small observational studies have reported no increase in adverse events when hyperthyroid patients undergo thyroidectomy. The aim of this study was to assess outcomes following total thyroidectomy in patients who were biochemically hyperthyroid at the time of surgery compared to those who were euthyroid. One hundred and fifty-one eligible patients undergoing thyroidectomy for hyperthyroidism between January 2012 and February 2016 were identified, of whom 57 were hyperthyroid on perioperative blood tests and 94 were euthyroid (comparison group). Primary outcomes were 30-day mortality, increased length of postoperative hospital stay and intraoperative signs consistent with thyrotoxicosis (e.g. heart rate 100 per minute, systolic blood pressure 180 or 60 mmHg, or temperature 38 degrees C). Secondary outcomes were intraoperative beta-blocker use and level of care required postoperatively. Thirty-day mortality was zero. The only significant difference between the two groups was a higher use of intraoperative beta-blockers amongst hyperthyroid patients (28.1% versus 8.5%, P=0.002). Our findings suggest that thyroidectomy for mild to moderate biochemical hyperthyroidism performed by an experienced thyroid surgeon and anaesthetist, is associated with increased intraoperative beta-blocker use but no statistical difference in mortality, length of postoperative stay or intraoperative signs consistent with thyrotoxicosis. While we still recommend attempting to achieve a euthyroid state whenever possible prior to thyroid surgery, mild to moderate degrees of residual biochemical hyperthyroidism when appropriately managed may not be associated with an increase in adverse outcomes.
机译:传统上,建议在甲状腺切除术之前进行甲状腺功能亢进患者的甲状腺功能亢进。然而,几个小的观察性研究报告说报告甲状腺功能亢进患者经历甲状腺切除术时,不良事件没有增加。本研究的目的是评估在术后生物化学甲状腺功能亢进的患者中的总甲状腺切除术后的结果,与术时是肠道的。确定了2012年1月和2016年2月在2012年1月至2016年2月之间进行甲状腺功能亢进术治疗甲状腺功能亢进的甲状腺功能亢进症的一百五十六个患者,其中57个甲状腺功能亢进血液试验,94例是Euthyroid(比较组)。主要结果是30天死亡率,术后医院住宿时间的长度增加和术中征象与甲状腺毒症一致(例如心率& 100每分钟100,收缩压& 180或& 60 mmH,或温度& 38℃) 。二次结果是术中β-阻滞剂使用和术后所需的护理水平。三十天的死亡率为零。两组之间的唯一巨大差异是甲状腺功能亢进患者中术中β-嵌体的唯一巨大差异(28.1%对8.5%,P = 0.002)。我们的研究结果表明,由经验丰富的甲状腺外科医生和麻醉师进行轻度至中度生化甲状腺功能亢进症的甲状腺切除术与增加的术中β-障碍剂使用,但没有统计差异,术后留下的长度或与甲状腺酸一致的术中迹象。虽然我们仍然建议在甲状腺手术前尽可能尝试实现Euthyroid状态,但是当适当管理时,温和至中等程度的残留生化甲状腺功能亢进可能与不良结果的增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号